|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices |
Alicia Morgans, MD, MPH and Neal Shore, MD, FACS
Urologist Neal Shore joins Alicia Morgans in a discussion on the integration of lutetium into clinical practices. Dr. Shore reviews the phase 3 VISION trial which led to the approval of Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. They discuss steps to thoughtfully and practically, integrate this new therapeutic into our treatment paradigm. |
|
|
|
|
|
|
|
|
|
|
|
Rucaparib Monotherapy Improves Radiographic Progression-Free Survival in Patients With Metastatic Castration-Resistant Prostate Cancer: TRITON3 Trial
|
Alicia Morgans, MD, MPH, and Alan Bryce, MD
Alicia Morgans and Alan Bryce highlight the TRITON3, phase 3, multicenter, open-label, randomized trial of Rubraca in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. |
|
|
|
|
|
|
|
|
|
|
| rPFS Improvement Regardless of Mutations in Biomarker Subgroups in the Phase III PROpel Trial in First-Line Therapy for Patients with mCRPC |
Fred Saad, MD, FRCS
Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). |
|
|
|
|
|
|
|
|
|
|
|
Combination Treatment Strategies with Radium-223 for mCRPC
|
Michael Morris, MD
Michael Morris joins Alicia Morgans in a discussion on combination therapies with Radium-223 for treating metastatic castration-resistant prostate cancer (mCRPC). Drs. Morris and Morgans highlight the DORA trial and focus on how combinations of treatment that either work by similar or different mechanisms of action can really amplify the survival benefits that we see with monotherapy approaches. |
|
|
|
|
|
|
|
|
|
|
| Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH
|
| Aaron Hansen BSc, MBBS, FRACP
|
| Aaron Hansen presents the first, preliminary results of the SPLASH trial assessing the radioligand 177Lu-PNT2002 (also known as 177Lu-PSMA I&T) in PSMA-positive patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed after treatment with androgen receptor axis-targeted therapy (ARAT). This first analysis presents the lead-in component of the phase 3 SPLASH trial.
|
|
|
|
|
|
|
|
|
|
|
| Detection of Mutations in Homologous Recombination Repair Genes in Tumour Tissue and Circulating Tumour DNA from Patients with Metastatic Castrate-Resistant Prostate Cancer in the Phase III PROpel Trial |
| Andrew J. Armstrong, MD, MSc |
| Andrew Armstrong presents the results of an analysis assessing tumor tissue-based and circulating tumor DNA (ctDNA)-based assessment of homologous recombination repair in patients enrolled in the Phase III PROpel trial assessing combination abiraterone and olaparib as first-line treatment in metastatic castrate-resistant prostate cancer (mCRPC). |
|
|
|
|
|
| Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
|
| Clara Hwang, MD |
| Clara Hwang presents an analysis of biomarker-directed therapy in men with metastatic castration-resistant prostate cancer (mCRPC). The authors conclude that, in a real-world mCRPC molecular profiling cohort, there are similar overall rates of actionable molecular alterations in non-Hispanic black and non-Hispanic white men, but higher rates of MMRd/MSI-H and lower frequency of PTEN alterations in non-Hispanic black men. Further, there was not evidence of differences in the delivery of targeted therapy. |
|
|
|
|
|
| Is There Still a Role for Radium-223? |
| Neal D. Shore, MD, FACS |
| Neal Shore discusses the role of radium-223 in the modern treatment armamentarium. He emphasized that mCRPC treatment decisions depend on prior treatments received. Radium-223 is a novel mechanism of action for treatment, which will not have previously been exhausted. There are many ongoing trials in both the mCRPC and metastatic castration sensitive space that will help better define the role of radium-223. |
|
|
|
|
|
|
